The substantial cash runway through 2029 provides significant operational flexibility and reduces near-term financing risk. Traders should monitor upcoming clinical data readouts in the second half of 2026, particularly the OLE study for ontunisertib and Phase 1b data for AGMB-447, which could serve as major catalysts. The successful IPO and extended runway position Agomab to execute its clinical strategy without immediate capital market dependence.
Price Chart
Executive Summary
Agomab Therapeutics reported its 2025 financial results and provided a 2026 outlook, highlighting a $208 million IPO that extends its cash runway into 2029, positive FDA interactions for its Phase 2b trial in Crohn's disease, and anticipated clinical data readouts in the second half of 2026. The company also confirmed its annual general meeting agenda, including board reappointments and auditor fee approval.
Key Facts
- Raised $208 million in gross proceeds from IPO in February 2026, extending cash runway into first half of 2029
- Cash and cash investments totaled €116.5 million as of December 31, 2025
- Positive FDA interactions on Phase 2b study design for ontunisertib in fibrostenosing Crohn's disease
- On track to initiate Phase 2b study with ontunisertib and Phase 2 study with AGMB-447 in IPF in second half of 2026
- Topline data from OLE study with ontunisertib and Phase 1b IPF cohort with AGMB-447 expected in second half of 2026
- Granted U.S. patent for AGMB-447 composition of matter
- Net loss was €62.5 million for 2025, compared to €46.3 million for 2024
Financial Impact
Raised $208 million in gross IPO proceeds, with cash position of €116.5 million as of December 31, 2025, expected to fund operations into first half of 2029
Risk Factors
- Clinical trial results may not meet expectations, particularly for the Phase 2b study in fibrostenosing Crohn's disease
- The company has no revenue and expects to continue incurring significant losses
- Dependence on successful regulatory interactions and trial outcomes for future progress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-048615 |
| Document: tm2612596d1_ex99-5.htm | 0001104659-26-048615 |
| Document: tm2612596d1_ex99-2.htm | 0001104659-26-048615 |
| Document: tm2612596d1_ex99-3.htm | 0001104659-26-048615 |
| Document: tm2612596d1_ex99-4.htm | 0001104659-26-048615 |
| Document: tm2612596d1_6k.htm | 0001104659-26-048615 |
| Document: 0001104659-26-048615-index-headers.html | 0001104659-26-048615 |
| Document: 0001104659-26-048615-index.html | 0001104659-26-048615 |
| Document: 0001104659-26-048615.txt | 0001104659-26-048615 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Insider Buy | $9.26 | awaiting T+5 | — | $8.57 (−7.45%) |
Oct 13, 2026 12d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 13, 2026 12d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 1, 2026 25d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Oct 1, 2026 25d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Sep 14, 2026 5w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 14, 2026 5w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $8.57 (−30.21%) |
Aug 10, 2026 10w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $8.57 (−42.29%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $8.57 (−32.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers